Cited by 236Breast Cancer Treatment StudiesEstrogen and related hormone effectsIron Metabolism and Disorders

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Open access

Habashy, Hany Onsy, Powe, Desmond G., Staka, Cindy M., Rakha, Emad A., Ball, Graham, Green, Andrew R., Aleskandarany, Mohammed, Paish, E. Claire, Douglas Macmillan, R., Nicholson, Robert I., Ellis, Ian O., Gee, Julia M. W.·2010·Breast Cancer Research and Treatment

DOI 10.1007/s10549-009-0345-x

Open this paper in CoChat — free account

Abstract

Transferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation. It may be implicated in promoting the growth of endocrine resistant phenotypes within ER+/luminal-like breast cancer. We used a panel of in vitro cell models of acquired resistance to tamoxifen (TAMR), Faslodex (FASR) or severe oestrogen deprivation (MCF-7X) and the ER+ luminal MCF-7 parental line to determine CD71 mRNA expression and to study transferrin (Tf) effects on in vitro tumour growth and its inhibition. Furthermore, CD71 protein expression was assessed in a well-characterized series of patients with invasive breast carcinoma using tissue microarrays. Our results demonstrated a striking elevation of CD71 in all cell models of acquired resistance. Exogenous Tf significantly promoted growth in MCF-7-X and MCF-7 cells but more so in MCF-7-X; this growth was significantly reduced by Faslodex (FAS) or a phosphoinositide-3 kinase inhibitor (LY294002). Increased CD71 expression was associated with poor NPI score, tumour proliferation, basal CKs, p53, EGFR, HER2, steroid receptor negativity and shortened breast cancer specific survival (P < 0.001). On multivariate analysis, CD71 was found to be an independent prognostic factor in the ER+ cohort of patients. In conclusion, therapies of current interest in breast cancer (e.g. FAS, PI3K-inhibitors) appear able to partially impact on transferrin/CD71-promoted growth, but further investigation of this important mitogenic mechanism may assist in designing new therapeutic strategies to target highly proliferative, endocrine resistant breast cancers. CD71 appears to be a candidate marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen.

Integrity signals

Registry

Crossref · 10.1007/s10549-009-0345-x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
Elston, C. W., & Ellis, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,181
Self-citation
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
Sotiriou, C. P., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A. A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 2,024
Pathological prognostic factors in breast cancer
Elston, C. W. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,744
Predicting the clinical status of human breast cancer by using gene expression profiles
West, M., Blanchette, C., Dressman, H. K., Huang, E. S., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Marks, J. R., & Nevins, J. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201162998 · Cited by 1,318
The Nottingham prognostic index in primary breast cancer
Galea, M. H., Blamey, R. W., Elston, C. W., & Ellis, I. O. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01840834 · Cited by 1,078
Self-citation
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027

Show all 44 references

Research works printed but not linked: 2

Lanson B, Drenou B, Gueret P, Amiot L, Bernard M, Dauriac C et al (1997) Prognostic value of CD71 expression in mantle cell lymphoma. Exp Hematol 25:401
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874. doi: 10.1073/pnas.191367098 · DOI

Sorted by citations

Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Iron and Cancer
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
Transferrin receptor 1 in cancer: a new sight for cancer therapy.
Shen, Y., Li, X., Dong, D., Zhang, B., Xue, Y., & Shang, P. (2018) · Europe PMC (PubMed Central) · Cited by 357
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
Gallium and its competing roles with iron in biological systems
Chitambar, C. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.027 · Cited by 287
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels‐Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 286
Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
Bae, S.-H., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E., Lee, K. C., & Youn, Y. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?
Bystrom, L. M., Guzman, M. L., & Rivella, S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5014 · Cited by 212
Role of ferritin alterations in human breast cancer cells
Shpyleva, S., Tryndyak, V., Kovalchuk, O., Starlard‐Davenport, A., Chekhun, V. F., Beland, F. A., & Pogribny, I. P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0849-4 · Cited by 205
Gallium-Containing Anticancer Compounds
Chitambar, C. R. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.69 · Cited by 201
Ferroptosis in Cancer Treatment: Another Way to Rome
Wu, Y., Yu, C., Luo, M., Chen, C., Qiu, J., Zhang, S., & Hu, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.571127 · Cited by 183
Nanoparticle-based drug delivery systems targeting cancer cell surfaces
Hong, L., Li, W., Li, Y., & Yin, S. (2023) · RSC Advances · doi:10.1039/d3ra02969g · Cited by 187
Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer
Jou, Y.-J., Lin, C.-D., Lai, C., Chen, C.-H., Kao, J., Chen, S., Tsai, M.-H., Huang, S., & Lin, C.-W. (2010) · Analytica Chimica Acta · doi:10.1016/j.aca.2010.09.030 · Cited by 159
The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?
Zhou, Y., Shen, Y., Chen, C., Sui, X., Yang, J., Wang, L., & Zhou, J. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0158 · Cited by 157
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters
Montaño-Samaniego, M., Bravo‐Estupiñan, D. M., Méndez-Guerrero, O., Alarcón-Hernández, E., & Ibáñez-Hernández, M. Á. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605380 · Cited by 159
Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo
Shibata, Y., Yasui, H., Higashikawa, K., Miyamoto, N., & Kuge, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225931 · Cited by 150
Laser-based 3D bioprinting for spatial and size control of tumor spheroids and embryoid bodies
Kingsley, D. M., Roberge, C. L., Rudkouskaya, A., Faulkner, D. E., Barroso, M., Intes, X., & Corr, D. T. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.014 · Cited by 133
A concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 130
Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor Population in Human Bone Marrow
Dinh, H. Q., Eggert, T., Meyer, M. A., Zhu, Y. P., Olingy, C. E., Llewellyn, R. A., Wu, R., & Hedrick, C. C. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.017 · Cited by 119
Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo
Wei, Y., Gu, X., Sun, Y., Meng, F., Storm, G., & Zhong, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.012 · Cited by 117
Iron homeostasis in breast cancer
Marques, O., da Silva, B. M., Porto, G., & Lopes, C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.029 · Cited by 116
Suicide Gene Therapy for Cancer; Old Dog New Tricks
Zarogoulidis, P. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000139 · Cited by 121
Macrophage iron homeostasis and polarization in the context of cancer
Jung, M., Mertens, C., & Brüne, B. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.09.011 · Cited by 105
Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism
Rychtarcikova, Z., Lettlova, S., Tomkova, V., Korenkova, V., Langerova, L., Simonova, E., Zjablovskaja, P., Alberich-Jorda, M., Neuzil, J., & Truksa, J. (2017) · Oncotarget · doi:10.18632/oncotarget.14093 · Cited by 100
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
Abduljabbar, R. F., Negm, O. H., Lai, C., Jerjees, D. A., Al-kaabi, M. M., Hamed, M. R., Tighe, P. J., Buluwela, L., Mukherjee, A., Green, A. R., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3335-1 · Cited by 103
Self-citation
Receptor-based Targeting of Therapeutics
Mehra, N. K., Mishra, V. K., & Jain, N. K. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.6 · Cited by 97
Iron metabolism and drug resistance in cancer
Kazan, H. H., Urfali‐Mamatoglu, C., & Gündüz, U. (2017) · BioMetals · doi:10.1007/s10534-017-0037-7 · Cited by 95
Receptor-Targeted Nanomedicine for Cancer Therapy
Prajapati, A., Rangra, S., Patil, R., Desai, N., Jyothi, V. G. S. S., Salave, S., Amate, P., Benival, D. M., & Kommineni, N. (2024) · Receptors · doi:10.3390/receptors3030016 · Cited by 101
Cellular Iron Metabolism in Prognosis and Therapy of Breast Cancer
Torti, S. V., & Torti, F. M. (2013) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2013007784 · Cited by 95
The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype
Habashy, H. O., Powe, D. G., Rakha, E. A., Ball, G., Macmillan, R. D., Green, A. R., & Ellis, I. O. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0419-9 · Cited by 91
Self-citation
High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines
Bajbouj, K., Shafarin, J., & Hamad, M. A. (2018) · Technology in Cancer Research & Treatment · doi:10.1177/1533033818764470 · Cited by 89
Cancer cells with irons in the fire
Bystrom, L. M., & Rivella, S. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.04.035 · Cited by 90
Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22323 · Cited by 87
Overexpression of transferrin receptor CD71 and its tumorigenic properties in esophageal squamous cell carcinoma
CHAN, K. T., Choi, M. Y., Lai, K., Tan, W., Tung, L. N., Lam, H. Y., Tong, D. K. H., Lee, N. P. Y., & Law, S. Y.-K. (2014) · Oncology Reports · doi:10.3892/or.2014.2981 · Cited by 86
Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
Mertens, C., Mora, J., Ören, B., Grein, S., Winslow, S., Scholich, K., Weigert, A., Malmström, P., Forsare, C., Fernö, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1408751 · Cited by 85
Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor Progression
Mertens, C., Akam, E. A., Rehwald, C., Brüne, B., Tomat, E., & Jung, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166164 · Cited by 83
Src Regulates Tyr20 Phosphorylation of Transferrin Receptor-1 and Potentiates Breast Cancer Cell Survival
Jian, J., Yang, Q., & Huang, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.271585 · Cited by 78
Emerging Mechanisms and Disease Implications of Ferroptosis: Potential Applications of Natural Products
Ge, C., Zhang, S., Mu, H., Shaojun, Z., Tan, Z., Huang, X., Chen, X., Zou, J., Zhu, Y., Dong, F., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.774957 · Cited by 80
TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer
Cheng, X., Fan, K., Wang, L., Ying, X., Sanders, A. J., Guo, T., Xing, X., Zhou, M., Du, H., Hu, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2272-z · Cited by 75
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells
Gallego‐Ortega, D., Ledger, A., Roden, D. L., Law, A. M. K., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S. L., Lee, H. J., Valdés‐Mora, F., et al. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002330 · Cited by 73
Self-citation
The iron chelator deferasirox synergises with chemotherapy to treat triple‐negative breast cancers
Tury, S., Assayag, F., Bonin, F., Château‐Joubert, S., Servely, J., Vacher, S., Becette, V., Caly, M., Rapinat, A., Gentien, D., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5104 · Cited by 71
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0194 · Cited by 72
Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2
Miyazawa, M., Bogdan, A. R., & Tsuji, Y. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.009 · Cited by 71
Deferoxamine Promotes MDA-MB-231 Cell Migration and Invasion through Increased ROS-Dependent HIF-1a Accumulation
Liu, Y., Cui, Y., Shi, M., Zhang, Q., Wang, Q., & Chen, X. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358674 · Cited by 69
Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy
Lelièvre, P., Sancey, L., Coll, J., Deniaud, A., & Busser, B. (2020) · Cancers · doi:10.3390/cancers12123524 · Cited by 69
Iron-Targeting Antitumor Activity of Gallium Compounds and Novel Insights Into Triapine ® -Metal Complexes
Chitambar, C. R., & Antholine, W. E. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4880 · Cited by 65
Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1α Inhibitor Impairs Pancreatic Tumor Growth
Lang, J., Zhao, X., Wang, X., Zhao, Y., Li, Y., Zhao, R., Cheng, K., Li, Y., Han, X., Zheng, X., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b08823 · Cited by 61
Lipocalin-2 and iron trafficking in the tumor microenvironment
Jung, M., Mertens, C., Bauer, R., Rehwald, C., & Brüne, B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.018 · Cited by 63
miR-148a regulates expression of the transferrin receptor 1 in hepatocellular carcinoma
Babu, K. R., & Muckenthaler, M. U. (2019) · Scientific Reports · doi:10.1038/s41598-018-35947-7 · Cited by 60
Transferrin receptor 1 targeted nanomedicine for brain tumor therapy
Li, J., Zhang, Z., Zhang, B., Yan, X., & Fan, K. (2023) · Biomaterials Science · doi:10.1039/d2bm02152h · Cited by 60
Quantitative Analysis of Transferrin Receptor 1 (TfR1) in Individual Breast Cancer Cells by Means of Labeled Antibodies and Elemental (ICP-MS) Detection
Corte‐Rodríguez, M., Blanco‐González, E., Bettmer, J., & Montes‐Bayón, M. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03438 · Cited by 58
Genome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks
Vidyasekar, P., Shyamsunder, P., Arun, R. P., Santhakumar, R., Kapadia, N. K., Kumar, R., & Verma, R. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135958 · Cited by 62
Regulation of transferrin receptor-1 mRNA by the interplay between IRE-binding proteins and miR-7/miR-141 in the 3′-IRE stem–loops
Miyazawa, M., Bogdan, A. R., Hashimoto, K., & Tsuji, Y. (2018) · RNA · doi:10.1261/rna.063941.117 · Cited by 53
Toxicity Tolerance in the Carcinogenesis of Environmental Cadmium
Ćirović, A., & Satarug, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031851 · Cited by 54
Cytotoxic Activities of Silver Nanoparticles and Silver Ions in Parent and Tamoxifen-Resistant T47D Human Breast Cancer Cells and Their Combination Effects with Tamoxifen against Resistant Cells.
Ostad, S. N., Dehnad, S., Nazari, Z. E., Tavajohi, S., Mokhtari, N., Shakibaie, M., & Shahverdi, A. R. (2010) · Europe PMC (PubMed Central) · Cited by 52
Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer
Bay (2009) · International Journal of Oncology · doi:10.3892/ijo_00000507 · Cited by 52
Iron, Oxidative Damage and Ferroptosis in Rhabdomyosarcoma
Fanzani, A., & Poli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081718 · Cited by 50
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype
Habashy, H. O., Powe, D. G., Glaab, E., Ball, G., Spiteri, I., Krasnogor, N., Garibaldi, J. M., Rakha, E. A., Green, A. R., Caldas, C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1073-y · Cited by 49
Self-citation
Deferoxamine Enhanced Mitochondrial Iron Accumulation and Promoted Cell Migration in Triple-Negative MDA-MB-231 Breast Cancer Cells Via a ROS-Dependent Mechanism
Chen, C., Wang, S., & Liu, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194952 · Cited by 49
DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy
Fang, C., Xu, D. H., Su, J., Dry, J. R., & Linghu, B. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00381-z · Cited by 53
Selection of superior targeting ligands using PEGylated PLGA nanoparticles for delivery of curcumin in the treatment of triple-negative breast cancer cells
Prabhuraj, R. S., Bomb, K., Srivastava, R., & Bandyopadhyaya, R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101722 · Cited by 48
Isolation, Characterization and Bioactivities of an Extracellular Polysaccharide Produced from Streptomyces sp. MOE6
Elnahas, M. O., Amin, M. A., Hussein, M., Shanbhag, V., Ali, A. E., & Wall, J. D. (2017) · Molecules · doi:10.3390/molecules22091396 · Cited by 49
Iron metabolism and the tumor microenvironment: A new perspective on cancer intervention and therapy (Review)
bu, X., & Wang, L. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5480 · Cited by 54
The iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in clear-cell renal cell carcinoma
Rehwald, C., Schnetz, M., Urbschat, A., Mertens, C., Meier, J. K., Bauer, R., Baer, P. C., Winslow, S., Roos, F. C., Zwicker, K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0655-7 · Cited by 44
Nrf2 Is a Potential Modulator for Orchestrating Iron Homeostasis and Redox Balance in Cancer Cells
Zhang, L., Zhang, J., Jin, Y., Yao, G., Zhao, H., Qiao, P., & Wu, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.728172 · Cited by 45
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Singh, S., Serwer, L., DuPage, A., Elkins, K., Chauhan, N., Ravn, M., Buchanan, F., Wang, L., Krimm, M., Wong, K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0193 · Cited by 41
Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway
Chen, C., Liu, P., Duan, X., Cheng, M. S., & Xu, L. X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s193507 · Cited by 41
Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials
Padayachee, J., & Singh, M. (2020) · Nanobiomedicine · doi:10.1177/1849543520983196 · Cited by 39
Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A‐431) cells
Tan, Y. R., Chiow, K. H., Huang, D., & Wong, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00627.x · Cited by 38
Harnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 37
An affordable label-free ultrasensitive immunosensor based on gold nanoparticles deposited on glassy carbon electrode for the transferrin receptor detection
Ahmad, A., Rabbani, G., Zamzami, M. A., Hosawi, S. B. I., Baothman, O. A. S., Altayeb, H. N., Akhtar, M. S. N., Ahmad, V., Khan, M. V., Khan, M. E., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133083 · Cited by 37
Inactivation of MYO5B Promotes Invasion and Motility in Gastric Cancer Cells
Dong, W., Chen, X., Chen, P., Yue, D., Zhu, L., & Fan, Q. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1989-z · Cited by 37
DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms
Lemler, D. J., Lynch, M. L., Tesfay, L., Deng, Z., Paul, B. T., Wang, X., Hegde, P., Manz, D. H., Torti, S. V., & Torti, F. M. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0814-9 · Cited by 38
Noninvasive 89 Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18 F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer
Henry, K. E., Dilling, T. R., Abdel-Atti, D., Edwards, K. J., Evans, M. J., & Lewis, J. S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192286 · Cited by 37
Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma
Xu, S., Wang, Z., Ye, J., Mei, S., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.729103 · Cited by 36
Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma
Shimosaki, S., Nakahata, S., Ichikawa, T., Kitanaka, A., Kameda, T., Hidaka, T., Kubuki, Y., Kurosawa, G., Zhang, L., Sudo, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.02.039 · Cited by 36
Doxorubicin–transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells
Wigner, P., Zieliński, K. W., Łabieniec-Watała, M., Marczak, A., & Szwed, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-84146-4 · Cited by 36
Smap1 deficiency perturbs receptor trafficking and predisposes mice to myelodysplasia
Kon, S., Minegishi, N., Tanabe, K., Watanabe, T., Funaki, T., Wong, W. F., Sakamoto, D., Higuchi, Y., Kiyonari, H., Asano, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63711 · Cited by 35
Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response
He, J., Whelan, S. A., Lu, M., Shen, D., Chung, D. U., Saxton, R. E., Faull, K. F., Whitelegge, J. P., & Chang, H. R. (2011) · International Journal of Proteomics · doi:10.1155/2011/896476 · Cited by 34
Engineered ferritin for lanthanide binding
Calisti, L., Trabuco, M. C., Boffi, A., Testi, C., Montemiglio, L. C., Georges, A. D., Benni, I., Ilari, A., Taciak, B., Białasek, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201859 · Cited by 34
Carcinogenesis as Side Effects of Iron and Oxygen Utilization: From the Unveiled Truth toward Ultimate Bioengineering
Toyokuni, S., Kong, Y., Cheng, Z., Sato, K., Hayashi, S., Ito, F., Jiang, L., Yanatori, I., Okazaki, Y., & Akatsuka, S. (2020) · Cancers · doi:10.3390/cancers12113320 · Cited by 33
Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer
Chen, F., Fan, Y., Hou, J., Liu, B., Zhang, B., Shang, Y., Chang, Y.-Z., Cao, P., & Tan, K. (2021) · Aging · doi:10.18632/aging.203512 · Cited by 33
L-ferritin: A theranostic agent of natural origin for MRI visualization and treatment of breast cancer
Bitonto, V., Alberti, D., Ruiu, R., Aime, S., Crich, S. G., & Cutrìn, J. C. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.051 · Cited by 32
Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma
Benadiba, J., Rosilio, C., Nebout, M., Heimeroth, V., Neffati, Z., Popa, A., Mary, D. A. S. G., Griessinger, E., Imbert, V., Sirvent, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239257 · Cited by 32
Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors
Pizzamiglio, S., Bortoli, M. D., Taverna, E., Signore, M., Veneroni, S., Cho, W., Orlandi, R., Verderio, P., & Bongarzone, I. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020410 · Cited by 32
Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1
Pham, D., Powell, J. A., Gliddon, B. L., Moretti, P. A. B., Tsykin, A., der Hoek, M. B. V., Kenyon, R. R., Goodall, G. J., & Pitson, S. M. (2013) · Oncogene · doi:10.1038/onc.2013.502 · Cited by 31
Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells
Hong, Y., Yang, J., Shen, X., Zhu, H., Sun, X., Wen, X., Bian, J., Hu, H., Yuan, L., Tao, J., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1337-y · Cited by 30
Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; “A Tight Partnership—Was Warburg Correct?”
Elliott, R. L., & Head, J. F. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.34039 · Cited by 30
CD71 in Gestational Pathology
Luchini, C., Parcesepe, P., Nottegar, A., Parolini, C., Mafficini, A., Remo, A., Chilosi, M., & Manfrin, E. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000175 · Cited by 30
Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro
Wu, Y., Xu, J., Chen, J., Zou, M., Rusidanmu, A., & Yang, R. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12572 · Cited by 31
Bionano Interactions of MCF-7 Breast Tumor Cells with a Transferrin Receptor Targeted Nanoparticle
Du, W., Fan, Y., He, B., Zheng, N., Yuan, L., Dai, W., Zhang, H., Wang, X., Wang, J., Zhang, X., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500796d · Cited by 29
Generating Giant Membrane Vesicles from Live Cells with Preserved Cellular Properties
Liu, Q., Bi, C., Li, J., Liu, X., Peng, R., Jin, C. Y., Sun, Y., Lyu, Y., Liu, H., Wang, H., et al. (2019) · Research · doi:10.34133/2019/6523970 · Cited by 32
Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer
Ziliotto, S., Gee, J. M. W., Ellis, I. O., Green, A. R., Finlay, P., Gobbato, A., & Taylor, K. M. (2019) · Metallomics · doi:10.1039/c9mt00136k · Cited by 29
Self-citation
The ITIM-Containing Receptor: Leukocyte-Associated Immunoglobulin-Like Receptor-1 (LAIR-1) Modulates Immune Response and Confers Poor Prognosis in Invasive Breast Carcinoma
Joseph, C., Alsaleem, M. A., Toss, M. S., Kariri, Y. A., Althobiti, M. M., Alsaeed, S. A., Aljohani, A., Narasimha, P. L., Mongan, N. P., Green, A. R., et al. (2020) · Cancers · doi:10.3390/cancers13010080 · Cited by 29
Self-citation
Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study
Buas, M. F., Rho, J.-H., Chai, X., Zhang, Y., Lampe, P. D., & Li, C. I. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3554-5 · Cited by 31
Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting
Fontana, F., Esser, A. K., Egbulefu, C., Karmakar, P. S., Su, X., Allen, J. S., Xu, Y., Davis, J. L., Gabay, A. J., Xiang, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293700 · Cited by 32
Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors
Arumov, A., Liyanage, P. Y., Trabolsi, A., Roberts, E. R., Li, L., Ferreira, B. C. L. B., Gao, Z., Ban, Y. J., Newsam, A. D., Taggart, M. W., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2674 · Cited by 28
Estrogen-induced disruption of intracellular iron metabolism leads to oxidative stress, membrane damage, and cell cycle arrest in MCF-7 cells
Bajbouj, K., Shafarin, J., Abdalla, M. Y., Ahmad, I. M., & Hamad, M. A. (2017) · Tumor Biology · doi:10.1177/1010428317726184 · Cited by 29
Myeloid deletion of phosphoinositide-dependent kinase-1 enhances NK cell-mediated antitumor immunity by mediating macrophage polarization
He, Y., Du, J., & Dong, Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774281 · Cited by 28

Authors: Habashy, H. O., Powe, D. G., Staka, C. M., Rakha, E. A., Ball, G., Green, A. R., Aleskandarany, M., Paish, E. C., Douglas Macmillan, R., Nicholson, R. I., Ellis, I. O., & Gee, J. M. W.
Affiliations: University of Nottingham (GB)
Cardiff University (GB)
Nottingham Trent University (GB)
Corresponding author: Ellis, Ian O.
ORCID: Habashy, Hany Onsy
Rakha, Emad A.
Ball, Graham
Green, Andrew R.
Aleskandarany, Mohammed
Ellis, Ian O.
Gee, Julia M. W.
Venue: Breast Cancer Research and Treatment
Publisher: Springer Science and Business Media LLC
Published: 2009-02-24
Volume: 119
Issue: 2
Pages: 283-293
ISSN: 0167-6806 (ISSN-L)
1573-7217
DOI: 10.1007/s10549-009-0345-x
OpenAlex: W2092206294
Cited by: 236
References: 44
Citations by year: 2026: 8 · 2025: 9 · 2024: 10 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 19 · 2019: 26 · 2018: 11 · 2017: 20 · 2016: 17 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 13
FWCI: 3.35
Type: journal article
Language: en
Open access: green
hal.science
Licence: other-oa
www.springer.com/tdm (tdm)
Locations: Breast Cancer Research and Treatment (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion, other-oa)
Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (submittedVersion)
Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords: transferrin receptor, breast cancer, tamoxifen resistance, endocrine therapy resistance, estrogen receptor-positive breast cancer, prognostic factors, transferrin, PI3K inhibitors, LY294002, fulvestrant, MCF-7 cells, tumour proliferation, breast cancer-specific survival, HER2, EGFR, p53
MeSH terms: Fulvestrant, Phosphoinositide-3 Kinase Inhibitors, Adult, Breast Neoplasms, Carcinoma, Chromones, Estradiol, Female, Flavonoids, Humans, Immunohistochemistry, Middle Aged, Morpholines, Neoplasm Invasiveness, Predictive Value of Tests, Receptors, Estrogen, Receptors, Transferrin, Retrospective Studies, RNA, Messenger, Tamoxifen, Time Factors, Transferrin, Biomarkers, Tumor, Antigens, CD, Gene Expression Regulation, Neoplastic, Proportional Hazards Models, Treatment Outcome, Risk Assessment, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Reverse Transcriptase Polymerase Chain Reaction, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Tissue Array Analysis, Protein Kinase Inhibitors, Cell Proliferation, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks